These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11821734)

  • 1. Benefit of transplantation in primary biliary cirrhosis between 1985-1997.
    Tinmouth J; Tomlinson G; Heathcote EJ; Lilly L
    Transplantation; 2002 Jan; 73(2):224-7. PubMed ID: 11821734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
    Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
    J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
    Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
    Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
    Poupon RE; Bonnand AM; Chrétien Y; Poupon R
    Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.
    Boberg KM; Wisløff T; Kjøllesdal KS; Støvring H; Kristiansen IS
    Aliment Pharmacol Ther; 2013 Oct; 38(7):794-803. PubMed ID: 23915021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis.
    Combes B; Luketic VA; Peters MG; Zetterman RK; Garcia-Tsao G; Munoz SJ; Lin D; Flye N; Carithers RL
    Am J Gastroenterol; 2004 Feb; 99(2):264-8. PubMed ID: 15046215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    Bosch A; Dumortier J; Maucort-Boulch D; Scoazec JY; Wendum D; Conti F; Morard I; Rubbia-Brandt L; Terris B; Radenne S; Abenavoli L; Poupon R; Chazouillères O; Calmus Y; Boillot O; Giostra E; Corpechot C
    J Hepatol; 2015 Dec; 63(6):1449-58. PubMed ID: 26282232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
    Battezzati PM; Zuin M; Crosignani A; Allocca M; Invernizzi P; Selmi C; Villa E; Podda M
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1427-34. PubMed ID: 11552915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
    Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
    Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management.
    Schreibman I; Regev A
    MedGenMed; 2006 May; 8(2):30. PubMed ID: 16926769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.
    Pedersen MR; Greenan G; Arora S; Murali AR; Mayo MJ
    Liver Transpl; 2021 Jun; 27(6):866-875. PubMed ID: 33185320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
    Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
    Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
    Papatheodoridis GV; Hadziyannis ES; Deutsch M; Hadziyannis SJ
    Am J Gastroenterol; 2002 Aug; 97(8):2063-70. PubMed ID: 12190178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results.
    Kaplan MM; Cheng S; Price LL; Bonis PA
    Hepatology; 2004 Apr; 39(4):915-23. PubMed ID: 15057894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
    Kilmurry MR; Heathcote EJ; Cauch-Dudek K; O'Rourke K; Bailey RJ; Blendis LM; Ghent CN; Minuk GY; Pappas SC; Scully LJ; Steinbrecher UP; Sutherland LR; Williams CN; Worobetz LJ
    Hepatology; 1996 May; 23(5):1148-53. PubMed ID: 8621147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.